Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Healthcare Biotechnology
Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

9342-8530 Quebec Inc
Bullboard Posts
User Avatar Image
(33)
•••
Comment by SurfForWealthon Dec 24, 2003 9:48am
241 Views
Post# 6817662

RE: RE: Payments

RE: RE: PaymentsChummy...good message. I agree with your points. A couple points of clarrification as I see them. Diagnocure is not hiring but in fact partnering with Gen-Probe. Gen-Probe has an amplification technology using DNA samples from the patient that will help the test detect cancer cells at an earlier stage & also produce better detection results than the current Gen 1 product from Diagnocure. Therefore the ratio of accurate testing will further increase. Gen-Probe also hopes to apply another technology they produce called Tigris which works to automate the testing process in order to save cost & speed up the process for the patient. While the existing Gen 1 product PCA3 appears to be superior & has FDA approval & is being currently sold, the Gen 2 product with Tigris delivery marketed world wide by Gen-Probe will be even better. Cheers!!!
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities